BUB chart, page-2747

"Bubs Supreme® will be on shelf in 500 Coles supermarkets from May 2022, adding to the shelf presence of existing Goat and Organic Grass Fed lines, now totaling nine Bubs® Infant Formula and Toddler Milk products.Bubs lead Corporate

Daigou distributor, Willis Trading, has committed to an opening Purchase Order valued at$32.9 million with the first containers already shipped and being sold in China from April."

When the quarterly came out it sounded good until you got to the numbers with increasing revenues but ended up losing cash YTD. But, after closer inspection of the report against the numbers, I am more positive about BUBs performance.

My analysis, which of course could be completely wrong but I'll hang it out anyway: If you look at most of the large numbers under section 1, Cash Flows, most 3rd qtr numbers equate to a third (~33%) of YTD which suggests to me that costs and receipts are running inline. The key exception here though is 'product manufacturing and operating costs', which is almost 1/2 YTD result @ 48.6%.

Taking into consideration the quote above re: Bubs Supreme, I suspect that BUBs has spent the money in producing product, where costs have been reported in qtr3 but receipts for sales coming in qtr4. I.E Daigou selling product from April (qtr4) where production would be in qtr3. Similar for stock heading to Coles in May.

If my assumptions are correct and the sales trends continue as per qtr3, then we should be looking at some strong results come EOY.

For safety sake though, DYOR but that's my take on the numbers YTD.

Although, I don't mind if the SP goes down somewhat so I can buy some more..